Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease
This study is currently recruiting participants.
Study NCT00004488 Information provided by FDA Office of Orphan Products Development
First Received: October 18, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gaucher's Disease
Osteopenia
Additional conditions recognized in this trial
Bone Diseases, Metabolic
Gaucher Disease
More general conditions related to this trial
Bone Diseases
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lipidoses
Lymphatic Diseases
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Musculoskeletal Diseases
Nervous System Diseases
Reticuloendotheliosis
Sphingolipidoses
Interventions listed in this trial
alendronate sodium
calcium carbonate
cholecalciferol
Additional drug interventions recognized in this trial
Alendronate
More general drug interventions related to this trial
Antacids
Bone Density Conservation Agents
Growth Substances
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins
Sponsors listed in this trial
FDA Office of Orphan Products Development
Children's Hospital Medical Center, Cincinnati
Back to top of Main Content
